Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001641172-25-025585
Filing Date
2025-08-26
Accepted
2025-08-26 17:24:20
Documents
17
Period of Report
2025-08-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A form8-ka.htm   iXBRL 8-K/A 42713
2 EX-4.1 ex4-1.htm EX-4.1 97420
3 EX-5.1 ex5-1.htm EX-5.1 23287
4 EX-10.1 ex10-1.htm EX-10.1 246445
5 EX-10.2 ex10-2.htm EX-10.2 88497
6 GRAPHIC ex5-1_001.jpg GRAPHIC 4542
  Complete submission text file 0001641172-25-025585.txt   770977

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE thar-20250826.xsd EX-101.SCH 3020
8 XBRL LABEL FILE thar-20250826_lab.xml EX-101.LAB 34239
9 XBRL PRESENTATION FILE thar-20250826_pre.xml EX-101.PRE 22362
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 4059
Mailing Address 245 MAIN STREET SUITE 204 CHESTER NJ 07930
Business Address 1200 ROUTE 22 EAST BRIDGEWATER NJ 08807 302-743-2995
Tharimmune, Inc. (Filer) CIK: 0001861657 (see all company filings)

EIN.: 842642541 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)